Stockscreener 앱 받기
3.92
4.16%
-0.17
전일 마감가:
$4.09
열려 있는:
$4.16
하루 거래량:
1.41M
Relative Volume:
0.61
시가총액:
$656.14M
수익:
$25.55M
순이익/손실:
$-341.97M
주가수익비율:
-1.40
EPS:
-2.8
순현금흐름:
$-304.44M
1주 성능:
-2.00%
1개월 성능:
-15.88%
6개월 성능:
-47.17%
1년 성능:
-62.60%
1일 변동 폭
$3.92
$4.24
1주일 범위
$3.85
$4.24
52주 변동 폭
$3.50
$11.02
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
399 BINNEY STREET, CAMBRIDGE
RLAY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.92 | 656.14M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-10 | 재개 | Goldman | Buy |
| 2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
Savant Capital LLC Buys Shares of 29,088 Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics (RLAY) Projected to Post Quarterly Earnings on Thursday - Defense World
The Potential Rise in the Price of Relay Therapeutics Inc (RLAY) following insiders activity - Knox Daily
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Nasdaq
Relay Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
This Insider Has Just Sold Shares In Relay Therapeutics - Simply Wall St
Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap DownTime to Sell? - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 75,324 Shares - MarketBeat
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 140,182 Shares of Stock - MarketBeat
Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock By Investing.com - Investing.com Australia
Relay Therapeutics: A Precision Oncology Play Worth The Risk - Seeking Alpha
Q2 Earnings Forecast for RLAY Issued By Leerink Partnrs - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down – Should You Sell? - Defense World
Q2 Earnings Estimate for RLAY Issued By Leerink Partnrs - Defense World
Quarterly Metrics: Quick and Current Ratios for Relay Therapeutics Inc (RLAY) - The Dwinnex
Brokers Issue Forecasts for RLAY Q1 Earnings - Defense World
RLAY’s Market Whiplash: 9.47% YTD Rise, -1.31% Plunge in 30 Days - The InvestChronicle
Analysts Set Expectations for RLAY Q1 Earnings - Armenian Reporter
Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - SETE News
BlackRock, Inc. Expands Stake in Relay Therapeutics Inc with Sig - GuruFocus.com
Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily
SG Americas Securities LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Brokerages - ETF Daily News
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
How should investors view Relay Therapeutics Inc (RLAY)? - US Post News
Is Relay Therapeutics Inc (NASDAQ: RLAY) Stock Worth Investing In for High Returns? - Marketing Sentinel
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 17,250 Shares - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 20,791 Shares - MarketBeat
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells 36,036 Shares of Stock - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing - Marketscreener.com
Relay Therapeutics Inc (RLAY) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin - BioCentury
Relay Therapeutics CEO Sanjiv Patel sells $1.76 million in stock - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down on Insider Selling - Defense World
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells $600,000.00 in Stock - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 6%Here's What Happened - MarketBeat
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Insider Selling - MarketBeat
Relay Therapeutics CEO Sanjiv Patel sells $1.76 million in stock By Investing.com - Investing.com UK
Relay Therapeutics (NASDAQ:RLAY) Trading 6.8% HigherHere's Why - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week LowShould You Sell? - MarketBeat
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
릴레이 테라퓨틱스 주식 (RLAY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Sanjiv | President and CEO |
Feb 13 '25 |
Sale |
3.70 |
75,324 |
278,699 |
883,089 |
| Rahmer Peter | See remarks |
Jan 29 '25 |
Sale |
4.55 |
26,541 |
120,762 |
419,681 |
| Rahmer Peter | See remarks |
Jan 30 '25 |
Sale |
4.42 |
17,250 |
76,245 |
402,431 |
| Rahmer Peter | See remarks |
Jan 28 '25 |
Sale |
4.63 |
1,673 |
7,746 |
307,081 |
| Catinazzo Thomas | Chief Financial Officer |
Jan 28 '25 |
Sale |
4.63 |
36,036 |
166,847 |
263,190 |
| Catinazzo Thomas | Chief Financial Officer |
Jan 30 '25 |
Sale |
4.42 |
20,791 |
91,896 |
379,431 |
| Catinazzo Thomas | Chief Financial Officer |
Jan 29 '25 |
Sale |
4.55 |
2,109 |
9,596 |
400,222 |
| Bergstrom Donald A | President, R&D |
Jan 29 '25 |
Sale |
4.55 |
46,407 |
211,152 |
646,861 |
| Bergstrom Donald A | President, R&D |
Jan 30 '25 |
Sale |
4.42 |
30,823 |
136,238 |
616,038 |
| Bergstrom Donald A | President, R&D |
Jan 28 '25 |
Sale |
4.63 |
3,220 |
14,909 |
516,868 |
0.27%
3.05%
자본화:
|
볼륨(24시간):